EVERSANA

Will you be at #ASH24? Be sure to attend the poster sessions to explore Pierantonio Russo MD, FCPP, FAAP, STS latest research and insights on the potential of targeted therapies for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Learn more or schedule a meeting with team EVERSANA at #ASH24: https://lnkd.in/gBMrD_kj

Heading to JPM and looking for partnership options for your asset? EVERSANA makes it easy! Whether you’re aiming to commercialize or build value for a sale or licensing deal, we’ve got you covered. With a flexible, ready-to-use commercial infrastructure and a team of experts, we’ve signed more than 20 partnerships in the last three years. Our model reduces financial risks and optimizes resources for successful product launches. Let’s connect at JPM in San Francisco from January 13 to 16 to discuss how we can work together! Send your appointment request: https://ow.ly/eyKi50Uf6Jg #Partnerships #Commercialization #JPM2025

Our latest white paper, “Evolving Approaches to Adherence in Oncology Clinical Pathways,” authored by Christopher Nuesch and Joey Pecoraro, examines the shift from traditional adherence tactics to more flexible, physician-friendly approaches. Key Takeaways: • The role of physician autonomy in pathway adherence • How health systems are balancing flexibility with adherence • Practical insights for pharmaceutical companies to adapt to these changes Stay informed and ahead of the curve in oncology care. Download now: https://ow.ly/cMf250U1GRS. #Oncology #ClinicalPathways

Revolutionizing Healthcare with AI! Abid Rahman discusses the transformative power of AI and machine learning. From enhancing marketing strategies to empowering healthcare providers and patients, this interview highlights the massive potential of generative AI. Explore more about our innovative offerings at https://lnkd.in/gCV3PZpY #HealthcareInnovation #AI #MachineLearning #FH24 Frontiers Health

How are drug manufacturers closing gaps in patient access, affordability and adherence? Attend Kevin O'Meara and Jim Burke's presentation to discover how commercialization models are personalizing patient care, improving healthcare accessibility and driving market momentum. Learn more and schedule time to connect with our experts on-site: https://ow.ly/5gti50U7TR2

Cheers, Great Place To Work UK! We couldn’t have done it without our spectacular team. They truly live our cultural beliefs and are making our mission of making a healthier world for all into a reality.     Learn more about our #GPTWCertified organization: https://lnkd.in/g83urHMY  #GPTW #Culture #WeAreEVERSANA 

At Trade and Channel Strategies, EVERSANA’s Paul Maurer and fellow industry leaders will discuss how to make the request for proposal (RFP) process more effective in obtaining comprehensive responses from potential distribution partners. The panel will explore best practices from key industry stakeholders, offering perspectives on effective questioning, essential documentation and criteria that align with strategic goals. These insights help streamline the selection process, making it more targeted and informative. Learn more about this panel session and schedule a meeting with our experts today: https://ow.ly/SYEz50U7TJG

At Frontiers Health 2024, our Chief Medical Officer, Pierantonio Russo MD, FCPP, FAAP, STS shared insights on how Machine Learning (ML) is transforming clinical outcomes. From predicting hospital readmissions to managing chronic diseases, ML is completely revolutionizing patient care. Watch the full video for more at https://lnkd.in/ggJHjeJ2 #MachineLearning #HealthcareInnovation #FH24

The #hematology and #oncology pipelines are constantly evolving. Is your commercial strategy equipped to navigate the challenges? Connect with our experts at #ASH24 to learn how our commercialization model is designed to address challenges with agility and data-driven solutions. Schedule a meeting: https://ow.ly/EhcA50TZiaK

We're excited to share our latest publication, "A Review of Indirect Treatment Comparisons (ITCs) in Regulatory Approval, Reimbursement, and Pricing Recommendations for Oncology Drugs." This comprehensive review highlights the critical role of ITCs in healthcare decision-making across the globe. Authored by our talented Value & Evidence team members: Krista Tantakoun, Christopher Olsen, Fatemeh Mirzayeh Fashami, Imtiaz Samjoo, and Chris Cameron, this work underscores the increasing importance of ITCs in supporting regulatory and reimbursement decisions for oncology drugs. Read now: https://lnkd.in/g8XAbBav #Oncology #RegulatoryAffairs #Reimbursement #Pricing #ITCs